Researchers are launching a groundbreaking trial using HIV drugs to treat neurofibromatosis 2 (NF2), a rare genetic condition causing multiple brain tumors along nerves. These non-cancerous growths lead to symptoms like balance issues, hearing loss, and chronic headaches, affecting about 1 in 25,000 to 40,000 people.
Current treatments for NF2 are limited to surgery, but a new study led by Professor Oliver Hanemann from the University of Plymouth's Brain Tumour Research Centre of Excellence aims to change that.
The trial will involve 12 patients, testing the drugs ritonavir and lopinavir, known for their ability to potentially shrink tumors.
Patients will undergo a 30-day regimen while researchers monitor the tumors' response through biopsies and blood tests before and after treatment.
Jayne Sweeney, 57, who has undergone multiple surgeries and chemotherapy for NF2-related tumors, expressed optimism about the trial.
She stated the profound impact of hearing loss caused by NF2, stressing the urgent need for more effective and less invasive treatment options.
The study builds upon promising lab findings suggesting these HIV drugs could also benefit other types of brain tumors, potentially offering a ray of hope for patients facing limited therapeutic options.
0 Comments